ALK B Stock Overview
Operates as an allergy solutions company in Europe, North America, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for ALK B from our risk checks.
ALK-Abelló A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 153.10 |
| 52 Week High | DKK 159.90 |
| 52 Week Low | DKK 69.90 |
| Beta | 0.58 |
| 11 Month Change | 1.12% |
| 3 Month Change | 23.37% |
| 1 Year Change | 105.64% |
| 33 Year Change | -0.20% |
| 5 Year Change | 97.80% |
| Change since IPO | 348.32% |
Recent News & Updates
Is ALK-Abelló (CPH:ALK B) Using Too Much Debt?
Jun 25
A Look At The Intrinsic Value Of ALK-Abelló A/S (CPH:ALK B)
Jun 07Recent updates
Is ALK-Abelló (CPH:ALK B) Using Too Much Debt?
Jun 25A Look At The Intrinsic Value Of ALK-Abelló A/S (CPH:ALK B)
Jun 07ALK-Abelló A/S (CPH:ALK B) Released Earnings Last Week And Analysts Lifted Their Price Target To kr.143
May 05ALK-Abelló A/S' (CPH:ALK B) Share Price Matching Investor Opinion
Apr 27ALK-Abelló A/S (CPH:ALK B) Shares Could Be 29% Below Their Intrinsic Value Estimate
Mar 06ALK-Abelló (CPH:ALK B) Has A Pretty Healthy Balance Sheet
Jan 19With ALK-Abelló A/S (CPH:ALK B) It Looks Like You'll Get What You Pay For
Jan 01Is ALK-Abelló (CPH:ALK B) A Risky Investment?
Sep 09ALK-Abelló (CPH:ALK B) Has A Pretty Healthy Balance Sheet
Jun 11Is ALK-Abelló A/S (CPH:ALK B) Trading At A 26% Discount?
May 24ALK-Abelló (CPH:ALK B) Has A Pretty Healthy Balance Sheet
Mar 12ALK-Abelló A/S (CPH:ALK B) Shares Could Be 26% Below Their Intrinsic Value Estimate
Feb 17Investors Interested In ALK-Abelló A/S' (CPH:ALK B) Earnings
Jan 30ALK-Abelló (CPH:ALK B) Seems To Use Debt Rather Sparingly
Dec 05Is ALK-Abelló A/S (CPH:ALK B) Trading At A 32% Discount?
Nov 11Does ALK-Abelló (CPH:ALK B) Have A Healthy Balance Sheet?
Sep 01Calculating The Fair Value Of ALK-Abelló A/S (CPH:ALK B)
Aug 05We Think ALK-Abelló (CPH:ALK B) Can Manage Its Debt With Ease
May 12Estimating The Fair Value Of ALK-Abelló A/S (CPH:ALK B)
Apr 21Is Now The Time To Put ALK-Abelló (CPH:ALK B) On Your Watchlist?
Mar 31Is ALK-Abelló (CPH:ALK B) A Risky Investment?
Dec 28Calculating The Intrinsic Value Of ALK-Abelló A/S (CPH:ALK B)
Dec 07Shareholder Returns
| ALK B | DK Pharmaceuticals | DK Market | |
|---|---|---|---|
| 7D | 5.5% | -0.05% | 0.2% |
| 1Y | 105.6% | 22.0% | 42.0% |
Return vs Industry: ALK B exceeded the Danish Pharmaceuticals industry which returned 22% over the past year.
Return vs Market: ALK B exceeded the Danish Market which returned 42% over the past year.
Price Volatility
| ALK B volatility | |
|---|---|
| ALK B Average Weekly Movement | 6.0% |
| Pharmaceuticals Industry Average Movement | 5.0% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in DK Market | 9.8% |
| 10% least volatile stocks in DK Market | 2.8% |
Stable Share Price: ALK B has not had significant price volatility in the past 3 months.
Volatility Over Time: ALK B's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1923 | 2,828 | Peter Halling | www.alk.net |
ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. Its product portfolio includes GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDARCURE, and ITULAZAX/ITULATEK for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including grass, ragweed, house dust mite, Japanese cedar, tree, and food.
ALK-Abelló A/S Fundamentals Summary
| ALK B fundamental statistics | |
|---|---|
| Market cap | DKK 33.86b |
| Earnings (TTM) | DKK 555.00m |
| Revenue (TTM) | DKK 4.94b |
61.0x
P/E Ratio6.9x
P/S RatioIs ALK B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALK B income statement (TTM) | |
|---|---|
| Revenue | DKK 4.94b |
| Cost of Revenue | DKK 1.82b |
| Gross Profit | DKK 3.13b |
| Other Expenses | DKK 2.57b |
| Earnings | DKK 555.00m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 23, 2024
| Earnings per share (EPS) | 2.51 |
| Gross Margin | 63.27% |
| Net Profit Margin | 11.23% |
| Debt/Equity Ratio | 4.2% |
How did ALK B perform over the long term?
See historical performance and comparison